Related Experiment Video
Updated: Dec 6, 2025

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
EPHA2 antisense RNA modulates EPHA2 mRNA levels in basal-like/triple-negative breast cancer cells
Tetsuya Okuyama1, Ryou Sakamoto2, Kazuhiro Kumagai2
1Medical Chemistry Laboratory, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, 525-8577, Japan.
Abstract:
Ephrin type-A receptor 2 (EPHA2) is a receptor tyrosine kinase (RTK), whose over-expression has been observed in a variety of cancers, including breast cancer. EPHA2 expression may be causally related to tumorigenesis; therefore, it is important to understand how EPHA2 gene (EPHA2) expression is regulated. Here, we report that EPHA2 antisense RNA (EPHA2-AS), a natural antisense transcript, is an important modulator of EPHA2 mRNA levels. EPHA2-AS is a ∼1.8 kb long non-coding RNA (lncRNA) with a poly(A) tail that encodes two splice variants, EPHA2-AS1/2. They are constitutively expressed in a concordant manner with EPHA2 mRNA in human breast adenocarcinoma cell lines and in patient samples, with the highest levels detected in the triple-negative breast cancer (TNBC) subtype. The silencing of EPHA2-AS1/2 by a sense oligonucleotide or over-expression of an antisense oligoribonucleotide, which were both designed from the EPHA2 mRNA region (nt 2955-2974) targeted by AS1/2, showed that EPHA2-AS1/2 modulated EPHA2 mRNA levels by interacting with the specific AS1/2-complementary region in the mRNA. The EPHA2-AS1/2 did not prevent microRNAs from acting on the relevant microRNA response elements shared by EPHA2-AS1/2 and EPHA2 mRNA. Our studies demonstrate a crucial role played by EPHA2-AS1/2 in modulating EPHA2 mRNA levels, and hence production of EPHA2 protein, a key oncogenic RTK that contributes to the tumorigenesis of TNBC cells.
Insights
A natural antisense RNA (EPHA2-AS) regulates Ephrin type-A receptor 2 (EPHA2) mRNA levels. This long non-coding RNA is crucial for EPHA2 protein production, impacting triple-negative breast cancer tumorigenesis.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Ephrin type-A receptor 2 (EPHA2) is a receptor tyrosine kinase (RTK) overexpressed in various cancers, including breast cancer.
- EPHA2's role in tumorigenesis necessitates understanding its gene expression regulation.
- Triple-negative breast cancer (TNBC) exhibits high EPHA2 levels.
Purpose of the Study:
- To investigate the role of EPHA2 antisense RNA (EPHA2-AS) in regulating EPHA2 mRNA levels.
- To determine the mechanism by which EPHA2-AS modulates EPHA2 expression.
- To assess the significance of EPHA2-AS in breast cancer, particularly TNBC.
Main Methods:
- Characterization of EPHA2-AS as a long non-coding RNA (lncRNA) with two splice variants (EPHA2-AS1/2).
- Analysis of EPHA2-AS and EPHA2 mRNA expression in breast cancer cell lines and patient samples.
- Experimental manipulation of EPHA2-AS levels using sense and antisense oligonucleotides.
- Investigation of EPHA2-AS interaction with EPHA2 mRNA and microRNA response elements.
Main Results:
- EPHA2-AS is constitutively expressed and concordant with EPHA2 mRNA, especially in TNBC.
- EPHA2-AS1/2 directly modulates EPHA2 mRNA levels through interaction with a complementary region.
- EPHA2-AS does not interfere with microRNA binding to shared response elements.
- EPHA2-AS plays a critical role in regulating EPHA2 protein production.
Conclusions:
- EPHA2-AS is a key regulator of EPHA2 mRNA and protein levels.
- EPHA2-AS contributes to the oncogenesis of TNBC by modulating EPHA2 expression.
- Understanding EPHA2-AS regulation offers potential therapeutic targets for breast cancer.
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Translational Regulation
MicroRNAs
MicroRNAs
Mitogens and the Cell Cycle
RNA Splicing

